Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Catalent, Adamas Enter CTM Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News

Catalent, Adamas Enter CTM Agreement

Catalent to manufacture ADS-5102 for Phase III trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent Pharma Solutions and Adamas Pharmaceuticals have entered an agreement for the manufacture of ADS-5102 (amantadine HCl) extended release capsules for Phase III trials. ADS-5102 is an investigational drug being developed for Levodopa-Induced Dyskinesia (LID) in patients with Parkinson’s disease.
 
“We believe Catalent’s capabilities make them the right choice to support execution of our upcoming clinical trials,” said Gregory T. Went, Ph.D., Adamas chairman and chief executive officer.
 
Barry Littlejohns, president of Catalent’s Advanced Delivery Technologies business, said, “Our controlled release formulation expertise and drug delivery technologies will ultimately benefit patients with better treatments. We are pleased Adamas selected Catalent for the development and supply of ADS-5102 which, if approved, will be the first medical treatment indicated for patients with LID in Parkinson’s disease.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics